Logo

Dyadic Pockets $12.6M in Private Stock Placement to Fund Tech Expansion

Nov 20, 2006
NEW YORK (GenomeWeb News) — Enzyme developer Dyadic International today said it has generated around $12.6 million in a private stock placement.
 
Dyadic said it will use roughly $12.3 million of the placement to expand its C1 Host Technology, which is used in the production of biomass production, and potentially in human antibody and therapeutic protein production.
 
The company also plans to use some funds to speed up the launch of new enzyme products, R&D and marketing.
 
The company said it has placed 2.7 million shares of common stock at $4.68 per share, and has granted warrants to buy up to 557,000 more shares.
 
The warrants may be exercised 181 days after the issue date and will expire three years after that at an exercise price at $6.33.

Breaking News
The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.